ResMed (MEX:RMD) PE Ratio: 19.56 (As of Jun. 24, 2026) — 47% Below Median


MEX:RMD ResMed Inc MEX:RMD
99 GF Score
Price MXN3,716.10
GF Value MXN5,298.64
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed PE Ratio?

ResMed MEX:RMD 99 PE Ratio is 19.56 as of Jun. 24, 2026, which is 47% below its 10-year median of 37.02. GuruFocus rates MEX:RMD with a GF Score™ of 99/100 and a GF Value™ of MXN5,298.64 (Significantly Undervalued). The stock has 1 warning sign investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-24), ResMed's share price is MXN3716.10. ResMed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN189.99. Therefore, ResMed's PE Ratio for today is 19.56.

Good Sign:

ResMed Inc stock PE Ratio (=18.44) is close to 10-year low of 18.19.

During the past 13 years, ResMed's highest PE Ratio was 91.30. The lowest was 18.19. And the median was 37.02.

ResMed's EPS (Diluted) for the three months ended in Mar. 2026 was MXN49.41. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN189.99.

As of today (2026-06-24), ResMed's share price is MXN3716.10. ResMed's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was MXN197.22. Therefore, ResMed's PE Ratio without NRI ratio for today is 18.84.

During the past 13 years, ResMed's highest PE Ratio without NRI was 55.50. The lowest was 17.51. And the median was 30.20.

ResMed's EPS without NRI for the three months ended in Mar. 2026 was MXN51.57. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was MXN197.22.

During the past 12 months, ResMed's average EPS without NRI Growth Rate was 18.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was 18.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 14.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 14.20% per year.

During the past 13 years, ResMed's highest 3-Year average EPS without NRI Growth Rate was 84.40% per year. The lowest was -24.10% per year. And the median was 19.70% per year.

ResMed's EPS (Basic) for the three months ended in Mar. 2026 was MXN49.41. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN190.27.

Back to Basics: PE Ratio


ResMed  (MEX:RMD) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


ResMed PE Ratio Related Terms


ResMed PE Ratio Historical Data

* Premium members only.

The historical data trend for ResMed's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed PE Ratio Chart

ResMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 76.09 39.55 35.88 27.66 27.13

ResMed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.12 27.13 28.02 23.82 21.65

MEX:RMD vs MDLN, WST, BDX: PE Ratio Comparison

For the Medical Instruments & Supplies subindustry, ResMed's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's PE Ratio distribution charts can be found below:

* The bar in red indicates where ResMed's PE Ratio falls into.


MEX:RMD
99GF Score
ResMed Inc MEX:RMD
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

ResMed's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=3716.10/189.987
=19.56

ResMed's Share Price of today is MXN3716.10.
ResMed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN189.99.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 19.56 mean?
ResMed (MEX:RMD) has a PE Ratio of 19.56 as of Jun. 24, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on ResMed and its competitors. This is 47% below median its historical median of 37.02. Over the past decade, ResMed's PE Ratio has ranged from 18.19 to 91.30.
Is ResMed's PE Ratio too high?
ResMed's current PE Ratio of 19.56 is 47% below median its 10-year median of 37.02. Over the past 10 years, this metric has ranged from a low of 18.19 to a high of 91.30. Overall, ResMed has a GF Score™ of 99/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's PE Ratio compare to MDLN and WST?
ResMed's PE Ratio of 19.56 can be compared against companies in the Medical Devices & Instruments industry. Historically, ResMed's own PE Ratio has ranged from 18.19 to 91.30 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Medical Devices & Instruments company?
A good PE Ratio depends on the Medical Devices & Instruments industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on ResMed and its competitors. ResMed's current PE Ratio is 19.56, which is 47% below median its own 10-year median of 37.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN5,298.64, compared to a current price of MXN3,716.10 — trading 29.9% below its estimated fair value. The current PE Ratio is 19.56, which is 47% below median its 10-year median of 37.02. ResMed's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For ResMed (MEX:RMD), the current PE Ratio is 19.56 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (MEX:RMD) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of MXN3,716.10 is trading 29.9% below its estimated GF Value™ of MXN5,298.64. GuruFocus considers ResMed to be Significantly Undervalued.

Key valuation signals for MEX:RMD:

  • PE Ratio: 19.56 (47% below median its 10-year median of 37.02)
  • GF Value™: MXN5,298.64 vs. price of MXN3,716.10 (29.9% below fair value)
  • GF Score™: 99/100 with 1 warning sign

No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
99GF Score

Get the complete analysis for MEX:RMD

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,716.10
Price
MXN5,298.64
GF Value